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Background: Acute coronary syndromes (ACS) gathered a major role in the triggering of clinical events (MACE) worldwide. Reinforcing the 
identification of the targets that require intervention is recommended.
Methods: ACCEPT (Acute Coronary Care Evaluation of Clinical Practice) is a nationwide registry sponsored by the Brazilian Society of Cardiology 
(SBC) aimed to identify the incorporation of evidence-based interventions in clinical practice. ACS patients treated in public and private hospitals 
were gathered in order to define demographic characteristics and cumulative occurrence of clinical events at 30-days up to 1-year follow-up. 
Multivariate analysis was performed in order to identify clinical predictors of MACE.
Results: ACS patients were enrolled in 46 Brazilian hospitals during one year (2010/2011). 
30-day Results 2,422 patients Unstable Angina (30.6%) Non STEMI (34.4%) STEMI (31.2%) P Value
Dual Antiplatelet Therapy at Admittance 89,0% 92,9% 97,2% <0,001
Heparin 85,9% 93,4% 87,9% <0,001
Beta blockers 81,7% 80,6% 77% 0,067
Statins 88,7% 89,9% 91,0% 0,338
Early Invasive Strategy plus Revascularization 37,3% 50,9% 74,0% <0,001
Total Death 2,6% 3,2% 5,1% 0,050
Reinfarction 2,4% 3,4% 2,9% 0,592
Stroke 0,5% 1,0% 0,6% 0,534
Combined 4,8% 7,5% 8,7% 0,024
Multivariate analysis identified that full adherence to evidence-based pharmacologic therapy (OR:0.58/CI95=0.39-0.85), early myocardial 
revascularization (OR: 0.67/CI95%=0.46-0.99) plus being treated in the south/southeast region of Brazil (OR:0.61/CI95%=0.40-0.92) were 
independent predictors that reduce the occurrence of 30-day MACE.
Conclusions: These findings praise the need to full appliance of guidelines recommendations, either in pharmacologic and invasive strategy 
prescription, in order to effectively reduce the burden impact of ACS. Health manager were strongly recommended to implement its correction.
